FoxM1 as a Novel Therapeutic Target for Cancer Drug Therapy

  • Xu, Xin-Sen (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University) ;
  • Miao, Run-Chen (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University) ;
  • Wan, Yong (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University) ;
  • Zhang, Ling-Qiang (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University) ;
  • Qu, Kai (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University) ;
  • Liu, Chang (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University)
  • Published : 2015.02.04


Background: Current cancer therapy mainly focuses on identifying novel targets crucial for tumorigenesis. The FoxM1 is of preference as an anticancer target, due to its significance in execution of mitosis, cell cycle progression, as well as other signal pathways leading to tumorigenesis. FoxM1 is partially regulated by oncoproteins or tumor suppressors, which are often mutated, lost, or overexpressed in human cancer. Since sustaining proliferating signaling is an important hallmark of cancer, FoxM1 is overexpressed in a series of human malignancies. Alarge-scale gene expression analysis also identified FoxM1 as a differentially-expressed gene in most solid tumors. Furthermore, overexpressed FoxM1 is correlated with the prognosis of cancer patients, as verified in a series of malignancies by Cox regression analysis. Thus, extensive studies have been conducted to explore the roles of FoxM1 in tumorigenesis, making it an attractive target for anticancer therapy. Several antitumor drugs have been reported to target or inhibit FoxM1 expression in different cancers, and down-regulation of FoxM1 also abrogates drug resistance in some cancer cell lines, highlighting a promising future for FoxM1 application in the clinic.


Supported by : national natural science foundation of China


  1. Wang Z, Ahmad A, Li Y, et al (2010). Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev, 36, 151-6.
  2. Wierstra I (2013a). FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res, 119, 191-419.
  3. Wierstra I (2013b). The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res, 118, 97-398.
  4. Wu QF, Liu C, Tai MH, et al (2010). Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol Sin, 31, 361-6.
  5. Wu XR, Chen YH, Liu DM, et al (2013). Increased expression of forkhead box M1 protein is associated with poor prognosis in clear cell renal cell carcinoma. Med Oncol, 30, 346.
  6. Xia JT, Wang H, Liang LJ, et al (2012a). Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas, 41, 629-35.
  7. Xia L, Huang W, Tian D, et al (2012b). Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J Hepatol, 57, 600-12.
  8. Xu N, Jia D, Chen W, et al (2013). FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis. PLoS One, 8, 59412.
  9. Xu N, Wu SD, Wang H, et al (2012). Involvement of FoxM1 in non-small cell lung cancer recurrence. Asian Pac J Cancer Prev, 13, 4739-43.
  10. Xue YJ, Xiao RH, Long DZ, et al (2012). Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med, 10, 200.
  11. Yang DK, Son CH, Lee SK, et al (2009). Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance. Hum Pathol, 40, 464-70.
  12. Yu J, Deshmukh H, Payton JE, et al (2011). Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res, 17, 1924-34.
  13. Zeng J, Wang L, Li Q, et al (2009). FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1. J Pathol, 218, 419-27.
  14. Zhang X, Zeng J, Zhou M, et al (2012). The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer, 11, 56.
  15. Penzo M, Massa PE, Olivotto E, et al (2009). Sustained NFkappaB activation produces a short-term cell proliferation block in conjunction with repressing effectors of cell cycle progression controlled by E2F or FoxM1. J Cell Physiol, 218, 215-27.
  16. Pignot G, Vieillefond A, Vacher S, et al (2012). Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br J Cancer, 106, 1177-86.
  17. Priller M, Poschl J, Abrao L, et al (2011). Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res, 17, 6791-801.
  18. Qu K, Xu X, Liu C, et al (2013). Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatininduced senescence in hepatocellular carcinoma. Cancer Lett, 331, 105-14.
  19. Radhakrishnan SK, Bhat UG, Hughes DE, et al (2006). Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res, 66, 9731-5.
  20. Ray-Coquard I, Ghesquiere H, Bachelot T, et al (2001). Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer, 85, 816-22.
  21. Sun H, Teng M, Liu J, et al (2011a). FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria. Cancer Lett, 306, 214-22.
  22. Sun HC, Li M, Lu JL, et al (2011b). Overexpression of forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma. Oncol Rep, 25, 1533-9.
  23. Takahashi K, Furukawa C, Takano A, et al (2006). The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res, 66, 9408-19.
  24. Topcul M, Cetin I (2014). Endpoint of cancer treatment: targeted therapies. Asian Pac J Cancer Prev, 15, 4395-403.
  25. Uddin S, Ahmed M, Hussain A, et al (2011). Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol, 178, 537-47.
  26. Uddin S, Hussain AR, Ahmed M, et al (2012). Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica, 97, 1092-100.
  27. Wang IC, Meliton L, Tretiakova M, et al (2008). Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene, 27, 4137-49.
  28. Wang R, Song Y, Xu X, et al (2013a). The expression of Nek7, FoxM1, and Plk1 in gallbladder cancer and their relationships to clinicopathologic features and survival. Clin Transl Oncol, 15, 626-32.
  29. Wang Y, Wen L, Zhao SH, et al (2013b). FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer, 79, 173-9.
  30. Koo CY, Muir KW, Lam EW (2012). FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta, 1819, 28-37.
  31. Korver W, Schilham MW, Moerer P, et al (1998). Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the winged-helix transcription factor Trident. Curr Biol, 8, 1327-30.
  32. Kwok JM, Peck B, Monteiro LJ, et al (2010). FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res, 8, 24-34.
  33. Li D, Wei P, Peng Z, et al (2013a). The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis. Clin Cancer Res, 19, 62-72.
  34. Li Q, Zhang N, Jia Z, et al (2009). Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res, 69, 3501-9.
  35. Li X, Qi W, Yao R, et al (2013b). Overexpressed transcription factor FOXM1 is a potential diagnostic and adverse prognostic factor in postoperational gastric cancer patients. Clin Transl Oncol, 16, 307-14.
  36. Lin M, Guo LM, Liu H, et al (2010). Nuclear accumulation of glioma-associated oncogene 2 protein and enhanced expression of forkhead-box transcription factor M1 protein in human hepatocellular carcinoma. Histol Histopathol, 25, 1269-75.
  37. Llaurado M, Majem B, Castellvi J, et al (2012). Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FOXM1 overexpression in ovarian cancer. Mol Cancer Res, 10, 914-24.
  38. Lok GT, Chan DW, Liu VW, et al (2011). Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One, 6, 23790.
  39. Major ML, Lepe R, Costa RH (2004). Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol, 24, 2649-61.
  40. Myatt SS, Lam EW (2007). The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer, 7, 847-59.
  41. Newick K, Cunniff B, Preston K, et al (2012). Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. PLoS One, 7, 39404.
  42. Okabe H, Satoh S, Kato T, et al (2001). Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res, 61, 2129-37.
  43. Okada K, Fujiwara Y, Takahashi T, et al (2013). Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol, 20, 1035-43.
  44. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.<2815::AID-SIM110>3.0.CO;2-8
  45. Bellelli R, Castellone MD, Garcia-Rostan G, et al (2012). FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat Cancer, 19, 695-710.
  46. Ahmed M, Uddin S, Hussain AR, et al (2012). FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma. J Clin Endocrinol Metab, 97, 1-13.
  47. Bektas N, Haaf A, Veeck J, et al (2008). Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer, 8, 42.
  48. Bhat UG, Halasi M, Gartel AL (2009). FoxM1 is a general target for proteasome inhibitors. PLoS One, 4, 6593.
  49. Calvisi DF, Pinna F, Ladu S, et al (2009). Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut, 58, 679-87.
  50. Chan DW, Yu SY, Chiu PM, et al (2008). Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol, 215, 245-52.
  51. Chu XY, Zhu ZM, Chen LB, et al (2012). FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem, 114, 755-62.
  52. Dang Y, Wang YC, Huang QJ (2014). Microarray and nextgeneration sequencing to analyse gastric cancer. Asian Pac J Cancer Prev, 15, 8033-9.
  53. Douard R, Moutereau S, Pernet P, et al (2006). Sonic hedgehogdependent proliferation in a series of patients with colorectal cancer. Surgery, 139, 665-70.
  54. Francis RE, Myatt SS, Krol J, et al (2009). FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol, 35, 57-68.
  55. Gialmanidis IP, Bravou V, Amanetopoulou SG, et al (2009). Overexpression of hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas. Lung Cancer, 66, 64-74.
  56. He SY, Shen HW, Xu L, et al (2012). FOXM1 promotes tumor cell invasion and correlates with poor prognosis in earlystage cervical cancer. Gynecol Oncol, 127, 601-10.
  57. Hui MK, Chan KW, Luk JM, et al (2012). Cytoplasmic forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma significantly correlates with pathological disease stage. World J Surg, 36, 90-7.
  58. Jiang LZ, Wang P, Deng B, et al (2011). Overexpression of forkhead Box M1 transcription factor and nuclear factorkappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Hum Pathol, 42, 1185-93.
  59. Kalinichenko VV, Gusarova GA, Tan Y, et al (2003). Ubiquitous expression of the forkhead box M1B transgene accelerates proliferation of distinct pulmonary cell types following lung injury. J Biol Chem, 278, 37888-94.
  60. Kim IM, Ackerson T, Ramakrishna S, et al (2006). The forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res, 66, 2153-61.

Cited by

  1. SUMO-specific protease 6 promotes gastric cancer cell growth via deSUMOylation of FoxM1 vol.36, pp.12, 2015,
  2. The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis vol.18, pp.1, 2019,